Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage LONDON and CHICAGO, May 25, 2023 (GLOBE NEWSWIRE) -- Renalytix (NASDAQ: RNLX) (LSE: RENX) , the first company to develop and commercialize an
By Steve Melendez|2023-05-30T06:56:07+00:0005.25.23|News|Comments Off on Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes
Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple Physician Specialties KidneyIntelX individualizes clinical decisions beginning at primary care where impacts of new therapies, blood pressure strategies and timely
In a clinical decision effectiveness study, KidneyIntelX classified more Black vs non-Black patients as high risk for progression of chronic kidney disease, resulting in increased prescription of SGLT2-inhibitor drug therapy Additional study results illustrate how KidneyIntelX is aligned with the
By Steve Melendez|2023-05-30T06:56:08+00:0004.12.23|News|Comments Off on Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
LONDON and SALT LAKE CITY, March 22, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that it will report its second quarter and first half fiscal year 2023 financial results on Thursday, March 30, 2023, before market open.